Overexpression of von Hippel-Lindau protein in skeletal muscles of patients with chronic obstructive pulmonary disease

Journal of Clinical Pathology

Volumn 62, Issue 1, 2009, Pages 70-76

  Jatta, K ^a   Eliason, G ^a   Portela Gomes, G M ^b   Grimelius, L ^b   Caro, O ^c   Nilholm, L ^c   Sirjso A ^a   Piehl Aulin, K ^a   Abdel Halim, S M ^a,c  

^a ÖREBRO UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CAPILLARY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SATELLITE CELL; TIBIALIS ANTERIOR MUSCLE;

AGED; ANTHROPOMETRY; BIOPSY; CAPILLARIES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMERASE CHAIN REACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 58349102711     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.057190     Document Type: Article

References (30)

1. Schols AMWJ, Soeters PB, Dingemans MC, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993;147:1151-6.
2. Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002;20:539-44.
3. Hansen MJ, Gualano RC, Bozinovski S, et al. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacol Ther 2006;109:162-72.
4. Schenkel NS, Burdet L, de Muralt B, et al. Oxygen saturation during daily activities in chronic obstructive pulmonary disease. Eur Respir J 1996;9:2584-9.
5. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. Respir Care 2000;45:39-51.
6. Gosker HR, Kubat B, Schaart G, et al. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. Eur Respir J 2003;22:280-5.
7. Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:617-25.
8. Pereira MC, Isayama RN, Seabra JC, et al. Distribution and morphometry of skeletal muscle fibres in patients with chronic obstructive pulmonary disease and chronic hypoxemia. Muscle Nerve 2004;30:796-8.
9. Somfay A, Porszasz J, Lee S-M, et al. Effect of hyperoxia on gas exchange and lactate kinetics following exercise onset in nonhypoxemic COPD patients. Chest 2002;121:393-400.
10. Jobin J, Maltais F, Doyon J-F, et al. Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. J Cardiopulm Rehabil 1998;18:432-7.
11. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998;30:1467-74.
12. Maynard MA, Oi H. Chung J. et al. Multiple splice variants of the human HIF-3 (alpha) locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003;278:11032-40.
13. Heidbreder M, Frohlich F, Johren 0, et al. Hypoxia rapidly activates HIF-3(alpha) mRNA expression. FASEB J 2003;17:1541-3.
14. Kondo K, Kaelin Jr WG. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25.
15. Karhausen J, Kong T, Narravula S, et al. Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression. J Cell Biochem 2005;95:1264-75.
16. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474-80.
17. Forsythe JA, Jiang B-H, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
18. Dhawan J, Rando TA. Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment. Trends Cell Biol 2005;15:666-73.
19. Rissanen TT, Vajanto I, Hiltunen M0, et al. Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischaemic skeletal muscle and its regeneration. Am J Pathol 2002;160:1393-403.
20. Germani A, Di Carlo A, Mangoni A, et al. Vascular endothelial growth factor modulates skeletal muscle myoblast function. Am J Pathol 2003;163:1417-28.
21. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires Notch signaling to maintain the undifferentiated cell state. Dev Cell 2005;9:617-28.
22. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
23. Henriksson KG. "Semi-open" muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 1979;59:317-23.
24. Kadi F, Hagg G, Hakansson R, et al. Structural changes in male trapezius muscle with work-related myalgia. Acta Neuropathol (Berl) 1998;95:352-60.
25. Charifi N, Kadi F, Feasson L, et al. Enhancement of microvessel tortuosity in the vastus lateralis muscle of old men in response to endurance training. J Physiol 2004;554:559-69.
26. Chazaud B, Sonnet C, Lafuste P, et al. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J Cell Biol 2003;163:1133-43.
27. Xia JH, Xie AN, Zhang KL, et al. The vascular endothelial growth factor expression and vascular regeneration in infarcted myocardium by skeletal muscle satellite cells. Chin Med J (Engl) 2006:119:117- 21.
28. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
29. Stroka DM, Burkhardt T. Desbaillets I, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 2001;15:2445-53.
30. Turcotte S, Desrosiers RR, Beliveau R. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol Renal Physiol 2004;286:F338-48.